For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
News Release
FDA commissioner resignation opens opportunity for refocus on science over politics
After a somewhat tumultuous tenure, FDA commissioner Marty Makary is stepping down. While Dr. Makary made his mission to accelerate drug approval and bring a…
Blog
Don’t hinder biosimilar development
In its most recent legislative session, the Florida legislature considered precluding pharmacy benefit managers (PBMs) from holding an investment interest in biosimilar manufacturing. That…
Blog
The unseen costs of banning PBM-owned pharmacies in Tennessee
Tennessee lawmakers recently passed the FAIR Rx Act, which would bar companies from owning pharmacies while also operating a pharmacy benefit manager (PBM) and…
Search Posts
Comment
Comments RE: Docket No. FDA–2023–N–2177 for “Medical Devices; Laboratory Developed Tests
I am an attorney with the Competitive Enterprise Institute. The Competitive Enterprise Institute is a non-profit research and advocacy organization that focuses on regulatory policy.
Washington Times
Better late than never: New York Times finally admits school shutdowns hurt children
The New York Times has made a “startling” discovery. Its editorial board has recognized that “school closures that took 50 million children out of classrooms…
City Journal
Not-So-Affordable Care
In a 2022 book, Seemed Like a Good Idea, health economist Mark Pauly and his University of Pennsylvania coauthors describe how health-care policymakers “often rely on…
News Release
CEI leads coalition calling on Congress to repeal drug price control provisions of the Inflation Reduction Act
The Competitive Enterprise Institute (CEI) and a coalition 43 conservative and free market groups sent a letter to Congress today calling for the…
Letters
Coalition Letter to End IRA Prescription Drug Price Controls
October 31, 2023 Dear Members of Congress, When the Inflation Reduction Act was passed and signed into law a year ago, the legislation granted the…
Blog
This week in ridiculous regulations: Blood donations to mortality tables
Poland voted its nationalist-populist government out of power. The US House of Representatives remained without a speaker, but with a lot of drama. Agencies issued…